FDA Generic, Biosimilar User Fees Could Be Locked Up Under Short-Term Funding Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
A continuing resolution does not specifically allow FDA to spend the fees, but the generic drug backlog and biosimilar product development fees are expected to be available.